Patents Assigned to New England Deaconess Hospital, Corp.
  • Patent number: 5852186
    Abstract: The present invention is directed to a recombinant human monoclonal antibody which binds to a discontinuous epitope on the HIV gp120 envelope glycoprotien, blocks the binding of gp120 to the CD4 receptor, and neutralizes a broad range of HIV isolates. The present invention also provides the primary nucleotide and deduced amino acid sequences of the rearranged heavy and light chains of the recombinant monoclonal antibody of the present invention, and a method of screening for antibodies which block binding of envelope glycoprotein to the CD4 receptor.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 22, 1998
    Assignees: Dana-Farber Cancer Insitute, New England Deaconess Hospital Corp.
    Inventors: Joseph G. Sodroski, Wayne A. Marasco, Marshall R. Posner, William A. Haseltine
  • Patent number: 5622991
    Abstract: An enteral diet containing fat in an amount to provide from 20 to 50% of total calories, said fat containing less than 15% polyunsaturated fat (e.g., palm oil or medium chain triglycerides) is administered to mediate amelioration of the inflammation associated with the inflammatory liver, pancreatic and intestinal disorders, e.g., to promote healing of the liver in alcoholic hepatitis.
    Type: Grant
    Filed: August 30, 1994
    Date of Patent: April 22, 1997
    Assignees: Cornell Research Foundation, Inc., New England Deaconess Hospital Corp.
    Inventors: Andrew J. Dannenberg, Amin A. Nanji
  • Patent number: 5413785
    Abstract: A method is provided for reducing the quantity of endotoxin circulating in the blood plasma of a living subject affected by an endotoxin-mediated clinical state. The method employs a formulated preparation comprising at least one persistent, acid-resistant, and colonizing Lactobacillus species in combination with a biocompatible carrier. The user then introduces the formulated preparation to the gastrointestinal tract of the subject on one or on multiple occasions.
    Type: Grant
    Filed: March 3, 1994
    Date of Patent: May 9, 1995
    Assignee: New England Deaconess Hospital Corp.
    Inventor: Amin A. Nanji
  • Patent number: 5320846
    Abstract: A method of treating patients with clinical disorder involving splanchnic disorders such as liver or gut dysfunction, the dysfunction being characterized by depletion of metabolic energy sources. The treatment involves the step of administering an effective amount of adenosine, or related nucleosides, to achieve and/or maintain normal metabolic levels of adenosine triphosphate (ATP) and/or its precursors in the patient's liver or other splanchnic organs. Administration may be as a total enteral nutritional diet, or as a dietary supplement. The invention includes a total enteral nutrition diet having nutritionally acceptable amounts of a lipid source, a protein source, a carbohydrate source, a vitamin source, and a mineral source, and an effective amount of adenosine to achieve normal metabolic levels of ATP and/or its precursors in ATP deficient organs of a recipient host.
    Type: Grant
    Filed: October 22, 1992
    Date of Patent: June 14, 1994
    Assignee: New England Deaconess Hospital Corp.
    Inventors: Bruce R. Bistrian, John D. Palombo
  • Patent number: 5312836
    Abstract: A new class of synthetic triglycerides, those having at least one short-chain (C.sub.2 -C.sub.5) fatty acid on a glycerol backbone, has been developed. These synthetic triglycerides (or structured lipids) are particularly useful in treating patients with intestinal problems.
    Type: Grant
    Filed: October 11, 1991
    Date of Patent: May 17, 1994
    Assignee: New England Deaconess Hospital Corp.
    Inventor: Bruce R. Bistrian
  • Patent number: 5278290
    Abstract: Disclosed is a protein that specifically binds carcinoembryonic actigen (CEA) in the presence of divalent cation in vitro. This protein has a molecular weight of about 21 kD as determined by SDS-polyacrylamide gel electrophoresis, is glycosylated, and includes the amino acid sequence set forth in the Sequence Listing as SEQ ID NO: 2. Also disclosed are antibodies that recognize the CEA binding protein, methods of detecting carcinoma, methods of treating carcinoma, and a kit for screening a patient for carcinoma.
    Type: Grant
    Filed: May 31, 1991
    Date of Patent: January 11, 1994
    Assignees: Applied Biotechnology, Inc., New England Deaconess Hospital, Corp.
    Inventors: Peter Thomas, Carol A. Toth, Sibusisiwe M. Maswoswe, Joseph V. Briggman